

17 Rec'd PCT/PTO *PCT* 04 OCT 2004

CASE D0185 US PCT
10/501035

CERTIFICATE OF MAILING

I hereby certify that the paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

9-27-04
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HUANG ET AL.

APPLICATION NO: 10/501,035

FILED: JULY 9, 2004

FOR: IDENTIFICATION OF POLYNUCLEOTIDES AND POLYPEPTIDE
FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT
WITH PROTEIN TYROSINE KINASES AND/OR PROTEIN
TYROSINE KINASE PATHWAYS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 9-27-04

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,444,887	4/24/84	Hoffmann			
	AB	4,474,893	10/2/84	Reading			
	AC	4,631,211	12/23/86	Houghten			
	AD	4,676,980	6/30/87	Segal et al.			
	AE	4,714,681	12/22/87	Reading			
	AF	4,716,111	12/29/87	Osband et al.			
	AG	4,741,900	5/3/88	Alvarez et al.			
	AH	4,816,397	3/28/89	Boss et al.			
	AI	4,816,567	3/28/89	Cabilly et al.			
	AJ	4,925,648	5/15/90	Hansen et al.			
	AK	4,946,778	8/7/90	Ladner et al.			
	AL	5,010,175	4/23/91	Rutter et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	EP 0 171 496	5/26/93	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 173 494	3/5/86	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 239 400	8/3/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	EP 0 307 434	7/29/98	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 0 322 094	12/2/92	EP			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Alizadeh, A.A. et al., "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, Vol. 403, pp. 503-511 (2000)
	AS	Ames, R.S. et al., "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins", Journal of Immunological Methods, Vol. 184, pp. 177-186 (1995)
	AT	Arnon, R. et al., "Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy", Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., publ., Reisfeld, R.A. et al., eds., pp. 243-256 (1985)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2AA	5,112,946	5/12/92	Maione			
	2AB	5,122,464	6/16/92	Wilson et al.			
	2AC	5,223,409	6/29/93	Ladner et al.			
	2AD	5,225,539	7/6/93	Winter			
	2AE	5,258,498	11/2/93	Huston et al.			
	2AF	5,288,514	2/22/94	Ellman			
	2AG	5,314,995	5/24/94	Fell, Jr. et al.			
	2AH	5,336,603	8/9/94	Capon et al.			
	2AI	5,349,053	9/20/94	Landolfi			
	2AJ	5,359,046	10/25/94	Capon et al.			
	2AK	5,403,484	4/4/95	Ladner et al.			
	2AL	5,413,923	5/9/95	Kucherlapati et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	2AM	EP 0 367 166	5/9/90	EP			<input type="checkbox"/>	<input type="checkbox"/>
	2AN	EP 0 394 827	10/31/90	EP			<input type="checkbox"/>	<input type="checkbox"/>
	2AO	EP 0 396 387	12/22/93	EP			<input type="checkbox"/>	<input type="checkbox"/>
	2AP	EP 0 413 622	2/11/98	EP			<input type="checkbox"/>	<input type="checkbox"/>
	2AQ	EP 0 439 095	5/20/98	EP			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	2AR	Ashkenazi, A. et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 10535-10539 (1991)
	2AS	Ausubel, F.M. et al., eds., Current Protocols in Molecular Biology, Vols. 1, 2, 3 and 4, John Wiley & Sons, Inc., publ., pp. 1-11 (table of contents) (2001)
	2AT	Ausubel, F.M. et al., eds., Unit 2.10: "Hybridization Analysis of DNA Blots", Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., publ., pp. 2.10.1-2.10.16 (1993)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	3AA	5,427,908	6/27/95	Dower et al.			
	3AB	5,447,851	9/5/95	Beutler et al.			
	3AC	5,474,981	12/12/95	Leder et al.			
	3AD	5,506,337	4/9/96	Summerton et al.			
	3AE	5,516,637	5/14/96	Huang et al.			
	3AF	5,519,134	5/21/96	Acevedo et al.			
	3AG	5,525,735	6/11/96	Gallop et al.			
	3AH	5,530,101	6/25/96	Queen et al.			
	3AI	5,539,083	7/23/96	Cook et al.			
	3AJ	5,545,806	8/13/96	Lonberg et al.			
	3AK	5,549,974	8/27/96	Holmes			
	3AL	5,565,332	10/15/96	Hoogenboom et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	3AM	EP 0 519 596	12/23/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	3AN	EP 0 592 106	4/13/94	EP			<input type="checkbox"/>	<input type="checkbox"/>
	3AO	WO 86/01533	3/13/86	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	3AP	WO 86/05807	10/9/86	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	3AQ	WO 87/02671	5/7/87	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	3AR	Ausubel, F.M. et al., eds., Unit 6.3: "Using DNA Fragments as Probes", Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., publ., pp. 6.3.1-6.3.6 (1993)
	3AS	Ausubel, F.M. et al., eds., Unit 10.8: "Immunoblotting and Immunodetection", Current Protocols in Molecular Biology, Vol. 2, John Wiley & Sons, Inc., publ., pp. 10.8.1-10.8.21 (1997)
	3AT	Ausubel, F.M. et al., eds., Unit 10.16: "Immunoprecipitation", Current Protocols in Molecular Biology, Vol. 2, John Wiley & Sons, Inc., publ., pp. 10.16.1-10.16.29 (1999)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4AA	5,569,588	10/29/96	Ashby et al.			
	4AB	5,569,825	10/29/96	Lonberg et al.			
	4AC	5,571,698	11/5/96	Ladner et al.			
	4AD	5,573,920	11/12/96	Randle			
	4AE	5,580,717	12/3/96	Dower et al.			
	4AF	5,585,089	12/17/96	Queen et al.			
	4AG	5,593,853	1/14/97	Chen et al.			
	4AH	5,601,819	2/11/97	Wong et al.			
	4AI	5,605,793	2/25/97	Stemmer			
	4AJ	5,622,929	4/22/97	Willner et al.			
	4AK	5,625,126	4/29/97	Lonberg et al.			
	4AL	5,633,425	5/27/97	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	4AM	WO 87/04462	7/30/87	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	4AN	WO 89/01036	2/9/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	4AO	WO 89/10404	11/2/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	4AP	WO 89/12624	12/28/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	4AQ	WO 90/02809	3/22/90	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	4AR	Ausubel, F.M. et al., eds., Unit 11.2: "Enzyme-Linked Immunosorbent Assays (ELISA)", Current Protocols in Molecular Biology, Vol. 2, John Wiley & Sons, Inc., publ., pp. 11.2.1-11.2.22 (1991)
	4AS	Baum, R., "Solid-phase synthesis of benzodiazepines", Chemical & Engineering News, pp. 33-34 (1993)
	4AT	Bebbington, C.R. et al., "High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker", Bio/Technology, Vol. 10, pp. 169-175 (1992)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5AA	5,652,361	7/29/97	Simon et al.			
	5AB	5,658,727	8/19/97	Barbas et al.			
	5AC	5,661,016	8/26/97	Lonberg et al.			
	5AD	5,698,426	12/16/97	Huse			
	5AE	5,733,743	3/31/98	Johnson et al.			
	5AF	5,750,753	5/12/98	Kimae et al.			
	5AG	5,756,065	5/26/98	Wilson et al.			
	5AH	5,766,883	6/16/98	Ballance et al.			
	5AI	5,780,225	7/14/98	Wigler et al.			
	5AJ	5,807,715	9/15/98	Morrison et al.			
	5AK	5,811,238	9/22/98	Stemmer et al.			
	5AL	5,814,318	9/29/98	Lonberg et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	5AM	WO 91/00360	1/10/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	5AN	WO 91/06570	5/16/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	5AO	WO 91/06657	5/16/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	5AP	WO 91/09967	7/11/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	5AQ	WO 91/10737	7/25/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	5AR	Bennett, D. et al., "Kinetic Characterization of the Interaction of Biotinylated Human Interleukin 5 with an Fc Chimera of its Receptor α Subunit and Development of an ELISA Screening Assay using Real-Time Interaction Biosensor Analysis", Journal of Molecular Recognition, Vol. 8, pp. 52-58 (1995)
	5AS	Better, M. et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment", Science, Vol. 240, pp. 1041-1043 (1988)
	5AT	Bibila, T.A. et al., "In Pursuit of the Optimal Fed-Batch Process for Monoclonal Antibody Production", Biotechnol. Prog., Vol. 11, No. 1, pp. 1-13 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6AA	5,821,047	10/13/98	Garrard et al.			
	6AB	5,830,721	11/3/98	Stemmer et al.			
	6AC	5,834,252	11/10/98	Stemmer et al.			
	6AD	5,837,458	11/17/98	Minshull et al.			
	6AE	5,876,969	3/2/99	Fleer et al.			
	6AF	5,885,793	3/23/99	Griffiths et al.			
	6AG	5,916,771	6/29/99	Hori et al.			
	6AH	5,939,598	8/17/99	Kucheralapati et al.			
	6AI	5,969,108	10/19/99	McCafferty et al.			
	6AJ	5,985,660	11/16/99	Galy			
	6AK	6,020,141	2/1/00	Pantoliano,et al.			
	6AL	6,036,920	3/14/00	Pantoliano et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	6AM	WO 91/10741	7/25/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	6AN	WO 91/14438	10/3/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	6AO	WO 91/19735	12/26/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	6AP	WO 92/00091	1/9/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	6AQ	WO 92/01047	1/23/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	6AR	Bitter, G.A. et al., "Expression and Secretion Vectors for Yeast", Methods in Enzymology, Vol. 153, pp. 516-544 (1987)
	6AS	Bittner, M. et al., "Molecular classification of cutaneous malignant melanoma by gene expression profiling", Nature, Vol. 406, pp. 536-540 (2000)
	6AT	Blanchard, A.P. et al., "Sequence to array: Probing the genome's secrets", Nature Biotechnology, Vol. 14, pp. 1649-1651 (1996)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	7AA	6,075,181	6/13/00	Kucherlapati et al.			
	7AB	6,114,598	9/5/00	Kucherlapati et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	7AM	WO 92/05793	4/16/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	7AN	WO 92/08495	5/29/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	7AO	WO 92/08802	5/29/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	7AP	WO 92/18619	10/29/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	7AQ	WO 92/22324	12/23/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	7AR	Blume-Jensen, P. et al., "Oncogenic kinase signalling", Nature, Vol. 411, pp. 355-365 (2001)
	7AS	Boulianne, G.L. et al., "Production of functional chimaeric mouse/human antibody", Nature, Vol. 312, pp. 643-646 (1984)
	7AT	Brinkmann, U. et al., "Phage display of disulfide-stabilized Fv fragments", Journal of Immunological Methods, Vol. 182, pp. 41-50 (1995)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	8AA	WO 93/11236	6/10/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AB	WO 93/17715	9/16/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AC	WO 93/20242	10/14/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AD	WO 93/21232	10/28/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AE	WO 95/15982	6/15/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AF	WO 95/20401	8/3/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AG	WO 96/04388	2/15/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AH	WO 96/22024	7/25/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AI	WO 96/33735	10/31/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AJ	WO 96/34096	10/31/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AK	WO 97/00271	1/3/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AL	WO 97/46251	12/11/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AM	WO 98/16654	4/23/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AN	WO 98/24893	6/11/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AO	WO 98/46645	10/22/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AP	WO 98/50433	11/12/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AQ	WO 99/04813	2/4/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	8AR	WO 00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	9AA	Brown, M.T. et al., "Regulation, substrates and functions of src", Biochimica et Biophysica Acta, Vol. 1287, pp. 121-149 (1996)
	9AB	Burton, D.R. et al., "Human Antibodies from Combinatorial Libraries", Advances in Immunology, Vol. 57, pp. 191-280 (1994)
	9AC	Calvo-Calle, J.M. et al., "Immunogenicity of Multiple Antigen Peptides Containing B and Non-Repeat T Cell Epitopes of the Circumsporozoite Protein of <i>Plasmodium falciparum</i> ", The Journal of Immunology, Vol. 150, No. 4, pp. 1403-1412 (1993)
	9AD	Campbell, D.A. et al., "Phosphonate Ester Synthesis Using a Modified Mitsunobu Condensation", J. Org. Chem., Vol. 59, No. 3, pp. 658-660 (1994)
	9AE	Chen, C. et al., "'Analogous' Organic Synthesis of Small-Compound Libraries: Validation of Combinatorial Chemistry in Small-Molecule Synthesis", J. Am. Chem. Soc., Vol. 116, No. 6, pp. 2661-2662 (1994)
	9AF	Chen, S.-Y. et al., "Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy", Human Gene Therapy, Vol. 5, pp. 595-601 (1994)
	9AG	Cho, C.Y. et al., "An Unnatural Biopolymer", Science, Vol. 261, pp. 1303-1305 (1993)
	9AH	Chothia, C. et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol., Vol. 196, pp. 901-917 (1987)
	9AI	Chothia, C. et al., "Conformations of immunoglobulin hypervariable regions", Nature, Vol. 342, pp. 877-883 (1989)
	9AJ	Chothia, C. et al., "Structural Determinants in the Sequences of Immunoglobulin Variable Domain", J. Mol. Biol., Vol. 278, pp. 457-479 (1998)
	9AK	Chow, M. et al., "Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 910-914 (1985)
	9AL	Cockett, M. et al., "Applied genomics: integration of the technology within pharmaceutical research and development", Current Opinion in Biotechnology, Vol. 11, pp. 602-609 (2000)
	9AM	Cockett, M.I. et al., "High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification", Bio/Technology, Vol. 8, pp. 662-667 (1990)
	9AN	Cohen, P.A. et al., "Characterization of a new intrabody directed against the N-terminal region of human p53", Oncogene, Vol. 17, pp. 2445-2456 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

10AA	Colbère-Garapin, F. et al., "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol., Vol. 150, pp. 1-14 (1981)
10AB	Cole, S.P.C. et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer", Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., publ., Reisfeld, R.A. et al., eds., pp. 77-96 (1985)
10AC	Coligan, J.E. et al., eds., Unit 7.22: "Generation of Epstein-Barr Virus (EBV) – Immortalized B Cell Lines", Current Protocols in Immunology, Vol. 1, John Wiley & Sons, Inc., publ., pp. 7.22.1-7.22.3 (1991)
10AD	Crouse, G.F. et al., "Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes", Molecular and Cellular Biology, Vol. 3, No. 2, pp. 257-266 (1983)
10AE	DeNardo, G.L. et al., "Comparison of 1,4,7,10-Tetraazacyclododecane- <i>N,N',N'',N'''</i> -tetraacetic acid (DOTA)-Peptide-ChL6, a Novel Immunoconjugate with Catabolizable Linker, to 2-Iminoethanol-2-[<i>p</i> -(Bromoacetamido)benzyl]-DOTA-ChL6 in Breast Cancer Xenografts", Clinical Cancer Research, Vol. 4, pp. 2483-2490 (1998)
10AF	DeWitt, S.H. et al., "Diversomers: An approach to nonpeptide, nonoligomeric chemical diversity", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6909-6913 (1993)
10AG	Dracopoli, N.C. et al., eds., Chapter 12: "Vectors for Gene Therapy", Current Protocols in Human Genetics, Vol. 3, John Wiley & Sons, Inc., publ., pp. 12.0.1-12.12.15 (1999)
10AH	Dracopoli, N.C. et al., eds., Chapter 13: "Delivery Systems for Gene Therapy", Current Protocols in Human Genetics, Vol. 3, John Wiley & Sons, Inc., publ., pp. 13.0.1-13.10.7 (1999)
10AI	Du Pasquier, L., Chapter 7: "Evolution of the Immune System", Fundamental Immunology, Second Edition, Raven Press Ltd., publ., Paul, W.E., ed., pp. 139-165 (1989)
10AJ	Fell, H.P. et al., "Genetic Construction and Characterization of a Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2", The Journal of Immunology, Vol. 146, No. 7, pp. 2446-2452 (1991)
10AK	Foecking, M.K. et al., "Powerful and versatile enhancer-promoter unit for mammalian expression vectors", Gene, Vol. 45, pp. 101-105 (1986)
10AL	Fountoulakis, M. et al., "Interferon γ Receptor Extracellular Domain Expressed as IgG Fusion Protein in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, Vol. 270, No. 8, pp. 3958-3964 (1995)
10AM	Francis, M.J. et al., "Immunological Priming with Synthetic Peptides of Foot-and-Mouth Disease Virus", J. Gen. Virol., Vol. 66, pp. 2347-2354 (1985)
10AN	Freeman, W.M. et al., "Fundamentals of DNA Hybridization Arrays for Gene Expression Analysis", BioTechniques, Vol. 29, No. 5, pp. 1042-1055 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

11AA	Furka, A. et al., "General method for rapid synthesis of multicomponent peptide mixtures", Int. J. Peptide Protein Res., Vol. 37, pp. 487-493 (1991)
11AB	Gentz, R. et al., "Bioassay for trans-activation using purified human immunodeficiency virus <i>tat</i> -encoded protein: Trans-activation requires mRNA synthesis", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 821-824 (1989)
11AC	Geysen, H.M. et al., "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 3998-4002 (1984)
11AD	Gillies, S.D. et al., "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 1428-1432 (1992)
11AE	Gillies, S.D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes", Journal of Immunological Methods, Vol. 125, pp. 191-202 (1989)
11AF	Goldspiel, B.R. et al., "Human Gene Therapy", Clinical Pharmacy, Vol. 12, pp. 488-505 (1993)
11AG	Golub, T.R. et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, Vol. 286, pp. 531-537 (1999)
11AH	Green, L.L., "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", Journal of Immunological Methods, Vol. 231, pp. 11-23 (1999)
11AI	Green, L.L. et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs", Nature Genetics, Vol. 7, pp. 13-21 (1994)
11AJ	Green, L.L. et al., "Regulation of B Cell Development by Variable Gene Complexity in Mice Reconstituted with Human Immunoglobulin Yeast Artificial Chromosomes", J. Exp. Med., Vol. 188, No. 3, pp. 483-495 (1998)
11AK	Greenspan, N.S. et al., "Idiotypes: structure and immunogenicity", The FASEB Journal, Vol. 7, pp. 437-444 (1993)
11AL	Hagihara, M. et al., "Vinylogous Polypeptides: An Alternative Peptide Backbone", J. Am. Chem. Soc., Vol. 114, No. 16, pp. 6568-6570 (1992)
11AM	Hämmerling, G.J. et al., eds., "Production of Antibody-Producing Hybridomas in the Rodent Systems", Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and technical advances, Elsevier/North-Holland Biomedical Press, publ., pp. 563-587 (1981)
11AN	Hansson, L.O. et al., "Evolution of Differential Substrate Specificities in Mu Class Glutathione Transferases Probed by DNA Shuffling", J. Mol. Biol., Vol. 287, pp. 265-276 (1999)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

12AA	Harayama, S., "Artificial evolution by DNA shuffling", TIBTECH, Vol. 16, pp. 76-82 (1998)
12AB	Harlow, E. et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, publ., pp. iii-ix (table of contents) (1988)
12AC	Hellström, K.E. et al., Chapter 15: "Antibodies for Drug Delivery", Controlled Drug Delivery: Fundamentals and Applications, Second Edition, Marcel Dekker, Inc., publ., Robinson, J.R. et al., eds., pp. 623-653 (1987)
12AD	Hirschmann, R. et al., "Nonpeptidal Peptidomimetics with a β -D-Glucose Scaffolding. A Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance P Antagonist", J. Am. Chem. Soc., Vol. 114, pp. 9217-9218 (1992)
12AE	Holliger, P. et al., "'Diabodies': Small bivalent and bispecific antibody fragments", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 6444-6448 (1993)
12AF	Houghten, R.A., "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 5131-5135 (1985)
12AG	Houghten, R.A. et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery", Nature, Vol. 354, pp. 84-86 (1991)
12AH	Huston, J.S. et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins", Methods in Enzymology, Vol. 203, pp. 46-88 (1991)
12AI	Inouye, S. et al., "Up-prompter mutations in the <i>lpp</i> gene of <i>Escherichia coli</i> ", Nucleic Acids Research, Vol. 13, No. 9, pp. 3101-3109 (1985)
12AJ	Janknecht, R. et al., "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 8972-8976 (1991)
12AK	Jespersen, L.S. et al., "Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen", Bio/Technology, Vol. 12, pp. 899-903 (1994)
12AL	Johanson, K. et al., "Binding Interactions of Human Interleukin 5 with Its Receptor α Subunit", The Journal of Biological Chemistry, Vol. 270, No. 16, pp. 9459-9471 (1995)
12AM	Kettleborough, C.A. et al., "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments", Eur. J. Immunol., Vol. 24, pp. 952-958 (1994)
12AN	Khan, J. et al., "Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks", Nature Medicine, Vol. 7, No. 6, pp. 673-679 (2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

13AA	Khan, J. et al., "Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays", Cancer Research, Vol. 58, pp. 5009-5013 (1998)
13AB	Köhler, G., "Immunoglobulin chain loss in hybridoma lines", Proc. Natl. Acad. Sci. USA, Vol. 77, No. 4, pp. 2197-2199 (1980)
13AC	Köhler, G. et al., "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pp. 495-497 (1975)
13AD	Kostelny, S.A. et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers", The Journal of Immunology, Vol. 148, No. 5, pp. 1547-1553 (1992)
13AE	Kozbor, D. et al., "The production of monoclonal antibodies from human lymphocytes", Immunology Today, Vol. 4, No. 3, pp. 72-79 (1983)
13AF	Kriegler, M., Gene Transfer and Expression: A Laboratory Manual, Stockton Press, publ., pp. vii-x (table of contents) (1990)
13AG	Kütemeier, G. et al., "Assembly of Humanized Antibody Genes from Synthetic Oligonucleotides Using a Single-Round PCR", BioTechniques, Vol. 17, No. 2, pp. 242-246 (1994)
13AH	Liang, R. et al., "Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library", Science, Vol. 274, pp. 1520-1522 (1996)
13AI	Lockhart, D.J. et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays", Nature Biotechnology, Vol. 14, pp. 1675-1680 (1996)
13AJ	Logan, J. et al., "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 3655-3659 (1984)
13AK	Lorenzo, M.D.M. et al., "PCR-Based Method for the Introduction of Mutations in Genes Cloned and Expressed in Vaccinia Virus", BioTechniques, Vol. 24, No. 2, pp. 308-313 (1998)
13AL	Lowy, I. et al., "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell, Vol. 22, pp. 817-823 (1980)
13AM	Marasco, W.A., "Intrabodies: turning the humoral immune system outside in for intracellular immunization", Gene Therapy, Vol. 4, pp. 11-15 (1997)
13AN	Mendez, M.J. et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice", Nature Genetics, Vol. 15, pp. 146-156 (1997)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

14AA	Morgan, R.A. et al., "Human Gene Therapy", Annu. Rev. Biochem., Vol. 62, pp. 191-217 (1993)
14AB	Morrison, S.J. et al., "Prospective Identification, Isolation by Flow Cytometry, and In Vivo Self-Renewal of Multipotent Mammalian Neural Crest Stem Cells", Cell, Vol. 96, pp. 737-749 (1999)
14AC	Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies", Science, Vol. 229, pp. 1202-1207 (1985)
14AD	Mulligan, R.C., "The Basic Science of Gene Therapy", Science, Vol. 260, pp. 926-932 (1993)
14AE	Mulligan, R.C. et al., "Selection for animal cells that express the <i>Escherichia coli</i> gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 4, pp. 2072-2076 (1981)
14AF	Mullinax, R.L. et al., "Expression of a Heterodimeric Fab Antibody Protein in One Cloning Step", BioTechniques, Vol. 12, No. 6, pp. 864-869 (1992)
14AG	Naramura, M. et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells", Immunology Letters, Vol. 39, pp. 91-99 (1994)
14AH	Neuberger, M.S. et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function", Nature, Vol. 314, pp. 268-270 (1985)
14AI	Nisonoff, A., "Idiotypes: Concepts and Applications", The Journal of Immunology, Vol. 147, No. 8, pp. 2429-2438 (1991)
14AJ	Ohage, E. et al., "Intrabody Construction and Expression. I. The Critical Role of V _L Domain Stability", J. Mol. Biol., Vol. 291, pp. 1119-1128 (1999)
14AK	Ohage, E.C. et al., "Intrabody Construction and Expression. II. A Synthetic Catalytic Fv Fragment", J. Mol. Biol., Vol. 291, pp. 1129-1134 (1999)
14AL	O'Hare, K. et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA, Vol. 78, No. 3, pp. 1527-1531 (1981)
14AM	Oi, V.T. et al., "Chimeric Antibodies", BioTechniques, Vol. 4, No. 3, pp. 214-221 (1986)
14AN	Order, S.E., Chapter 15: "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", Monoclonal Antibodies for Cancer Detection and Therapy, Academic Press Inc., publ., Baldwin, R.W. et al., eds., pp. 303-316 (1985)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

15AA	Padlan, E.A., "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties", Molecular Immunology, Vol. 28, No. 4/5, pp. 489-498 (1991)
15AB	Patten, P.A. et al., "Applications of DNA shuffling to pharmaceuticals and vaccines", Current Opinion in Biotechnology, Vol. 8, pp. 724-733 (1997)
15AC	Persic, L. et al., "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries", Gene, Vol. 187, pp. 9-18 (1997)
15AD	Peterson, J.J. et al., "Enzymatic Cleavage of Peptide-Linked Radiolabels from Immunoconjugates", Bioconjugate Chemistry, Vol. 10, No. 4, pp. 553-557 (1999)
15AE	Proba, K. et al., "Antibody scFv Fragments Without Disulfide Bonds Made by Molecular Evolution", J. Mol. Biol., Vol. 275, pp. 245-253 (1998)
15AF	Proudfoot, N.J., "Transcriptional interference and termination between duplicated α -globin gene constructs suggests a novel mechanism for gene regulation", Nature, Vol. 322, pp. 562-565 (1986)
15AG	Riechmann, L. et al., "Reshaping human antibodies for therapy", Nature, Vol. 332, pp. 323-327 (1988)
15AH	Riss, T.L. et al., "Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays", Mol. Biol. Cell, Vol. 3 (Supp.), No. 1067, p. 184a (1992)
15AI	Roguska, M.A. et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing", Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 969-973 (1994)
15AJ	Rondon, I.J. et al., "Intracellular Antibodies (Intrabodies) for Gene Therapy of Infectious Diseases", Annu. Rev. Microbiol., Vol. 51, pp. 257-283 (1997)
15AK	Rüther, U. et al., "Easy identification of cDNA clones", The EMBO Journal, Vol. 2, No. 10, pp. 1791-1794 (1983)
15AL	Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Books 1, 2, and 3, Cold Spring Harbor Laboratory Press, publ., pp. xi-xxxviii (table of contents) (1989)
15AM	Santerre, R.F. et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene, Vol. 30, pp. 147-156 (1984)
15AN	Sawai, H. et al., "Direct Production of the Fab Fragment Derived From the Sperm Immobilizing Antibody Using Polymerase Chain Reaction and cDNA Expression Vectors", American Journal of Reproductive Immunology, Vol. 34, pp. 26-34 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

16AA	Schena, M. et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray", Science, Vol. 270, pp. 467-470 (1995)
16AB	Shipp, M.A. et al., "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning", Nature Medicine, Vol. 8, No. 1, pp. 68-74 (2002)
16AC	Shu, L. et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 7995-7999 (1993)
16AD	Skerra, A. et al., "Assembly of a Functional Immunoglobulin F _v Fragment in <i>Escherichia coli</i> ", Science, Vol. 240, pp. 1038-1041 (1988)
16AE	Smith, A.D. et al., "Human Rhinovirus Type 14: Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1", Journal of Virology, Vol. 72, No. 1, pp. 651-659 (1998)
16AF	Smith, A.D. et al., "Protein Engineering to Create Biologically Active Peptides: Recombinant Human Rhinoviruses that Display Peptide Sequences", Behring Inst. Mitt., No. 98, pp. 229-239 (1997)
16AG	Songsivilai, S. et al., "Bispecific antibody: a tool for diagnosis and treatment of disease", Clin. Exp. Immunol., Vol. 79, pp. 315-321 (1990)
16AH	Sonneveld, P., "Multidrug resistance in haematological malignancies", Journal of Internal Medicine, Vol. 247, pp. 521-534 (2000)
16AI	Sørli, T. et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc. Natl. Acad. Sci., Vol. 98, No. 19, pp. 10869-10874 (2001)
16AJ	Stephens, P.E. et al., "The construction of a highly efficient and versatile set of mammalian expression vectors", Nucleic Acids Research, Vol. 17, No. 17, p. 7110 (1989)
16AK	Studnicka, G.M. et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues", Protein Engineering, Vol. 7, No. 6, pp. 805-814 (1994)
16AL	Sutcliffe, J.G. et al., "Antibodies That React with Predetermined Sites on Proteins", Science, Vol. 219, pp. 660-666 (1983)
16AM	Szybalska, E.H. et al., "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci., Vol. 48, pp. 2026-2034 (1962)
16AN	Tam, J.P. et al., "Chemoselective Approaches to the Preparation of Peptide Dendrimers and Branched Artificial Proteins Using Unprotected Peptides as Building Blocks", Biomedical Peptides, Proteins & Nucleic Acids, Vol. 1, No. 3, pp. 123-132 (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

17AA	Thorpe, P.E., "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological and Clinical Applications, Editrice Kurtis s.r.l., publ., Pinchera, A. et al., eds., pp. 475-506 (1985)
17AB	Thorpe, P.E. et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates", Immunological Rev., Vol. 62, pp. 119-158 (1982)
17AC	TIBTECH, Vol. 11, No. 5, pp. 155-215 (1993)
17AD	Tolstoshev, P., "Gene Therapy, Concepts, Current Trials and Future Directions", Annu. Rev. Pharmacol. Toxicol., Vol. 32, pp. 573-596 (1993)
17AE	Traunecker, A. et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells", The EMBO Journal, Vol. 10, No. 12, pp. 3655-3659 (1991)
17AF	Traunecker, A. et al., "Janusin: New Molecular Design for Bispecific Reagents", Int. J. Cancer, Supp. 7, pp. 51-52 (1992)
17AG	Traunecker, A. et al., "Soluble CD4 molecules neutralize human immunodeficiency virus type 1", Nature, Vol. 331, pp. 84-86 (1988)
17AH	Tutt, A. et al., "Trispecific F(ab') ₃ Derivatives That Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells", The Journal of Immunology, Vol. 147, No. 1, pp. 60-69 (1991)
17AI	Van Heeke, G. et al., "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ", The Journal of Biological Chemistry, Vol. 264, No. 10, pp. 5503-5509 (1989)
17AJ	van 't Veer, L.J. et al., "Gene expression profiling predicts clinical outcome of breast cancer", Nature, Vol. 415, pp. 530-536 (2002)
17AK	Vaughan, T.J. et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", Nature Biotechnology, Vol. 14, pp. 309-314 (1996)
17AL	Vié, H. et al., "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 11337-11341 (1992)
17AM	Wands, J.R. et al., "High Affinity Monoclonal Antibodies to Hepatitis B Surface Antigen (HB _s Ag) Produced by Somatic Cell Hybrids", Gastroenterology, Vol. 80, No. 2, pp. 225-232 (1981)
17AN	West, M. et al., "Predicting the clinical status of human breast cancer by using gene expression profiles", Proc. Natl. Acad. Sci., Vol. 98, No. 20, pp. 11462-11467 (2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

18AA	Wigler, M. et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell, Vol. 11, pp. 223-232 (1977)
18AB	Wilson, I.A. et al., "The Structure of an Antigenic Determinant in a Protein", Cell, Vol. 37, pp. 767-778 (1984)
18AC	Wirtz, P. et al., "Intrabody construction and expression III: Engineering hyperstable V _H domains", Protein Science, Vol. 8, pp. 2245-2250 (1999)
18AD	Wu, G.Y. et al., "Delivery Systems for gene therapy", Biotherapy, Vol. 3, pp. 87-95 (1991)
18AE	Zhang, A. et al., "A Disulfide-Bound HIV-1 V3 Loop Sequence on the Surface of Human Rhinovirus 14 Induces Neutralizing Responses against HIV-1", Biol. Chem., Vol. 380, pp. 365-374 (1999)
18AF	Zheng, X.X. et al., "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-Induced Septic Shock and Allogeneic Islet Transplantation", The Journal of Immunology, Vol. 154, pp. 5590-5600 (1995)
18AG	Zhu, Q. et al., "Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7", Journal of Immunological Methods, Vol. 231, pp. 207-222 (1999)
18AH	Zimmermann, J., "Refining the Toolbox for HTS", Genetic Engineering News, Vol. 20, No. 8, pp. 13, 40, 69 (April 15, 2000)
18AI	Zimmermann, K. et al., "A Triglycine Linker Improves Tumor Uptake and Biodistributions of 67-Cu-Labeled Anti-Neuroblastoma MAb chCE7 F(ab') ₂ Fragments", Nuclear Medicine & Biology, Vol. 26, pp. 943-950 (1999)
18AJ	Zurfluh, L.L. et al., "Auxin-induced changes in the patterns of protein synthesis in soybean hypocotyl", Proc. Natl. Acad. Sci. USA, Vol. 77, No. 1, pp. 357-361 (1980)
18AK	NCBI ENTREZ ACCESSION NO. gi AA418437, Hillier, L. et al., May 12, 1997
18AL	NCBI ENTREZ ACCESSION NO. gi AA595596, NCI-CGAP, September 12, 1997
18AM	NCBI ENTREZ ACCESSION NO. gi AA873266, NCI-CGAP, April 21, 1998
18AN	NCBI ENTREZ ACCESSION NO. gi AB000449, Nezu, J. et al., February 5, 1999

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

19AA	NCBI ENTREZ ACCESSION NO. gi AB006622, Ohara, O. et al., October 6, 2001
19AB	NCBI ENTREZ ACCESSION NO. gi AB006626, Ohara, O. et al., October 6, 2001
19AC	NCBI ENTREZ ACCESSION NO. gi AB007870, Ishikawa, K. et al., January 10, 2004
19AD	NCBI ENTREZ ACCESSION NO. gi AB007960, Seki, N. et al., August 13, 1998
19AE	NCBI ENTREZ ACCESSION NO. gi AB008515, Nakamura, M. et al., August 10, 2001
19AF	NCBI ENTREZ ACCESSION NO. gi AB009010, Kim, N. et al., July 26, 2001
19AG	NCBI ENTREZ ACCESSION NO. gi AB009282, Ishibashi, K., December 5, 1997
19AH	NCBI ENTREZ ACCESSION NO. gi AB009426, Fujino, T. et al., April 14, 2000
19AI	NCBI ENTREZ ACCESSION NO. gi AB011114, Nagase, T. et al., July 5, 2002
19AJ	NCBI ENTREZ ACCESSION NO. gi AB011123, Nagase, T. et al., May 10, 2002
19AK	NCBI ENTREZ ACCESSION NO. gi AB011535, Nakayama, M. et al., August 22, 1998
19AL	NCBI ENTREZ ACCESSION NO. gi AB014511, Ishikawa, K. et al., July 15, 1998
19AM	NCBI ENTREZ ACCESSION NO. gi AB014519, Ishikawa, K. et al., January 10, 2004
19AN	NCBI ENTREZ ACCESSION NO. gi AB014520, Ishikawa, K. et al., February 6, 1999

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

20AA	NCBI ENTREZ ACCESSION NO. gi AB014529, Ishikawa, K. et al., May 10, 2002
20AB	NCBI ENTREZ ACCESSION NO. gi AB014557, Ishikawa, K. et al., May 10, 2002
20AC	NCBI ENTREZ ACCESSION NO. gi AB014558, Ishikawa, K. et al., February 6, 1999
20AD	NCBI ENTREZ ACCESSION NO. gi AB014566, Ishikawa, K. et al., February 6, 1999
20AE	NCBI ENTREZ ACCESSION NO. gi AB014585, Ishikawa, K. et al., January 10, 2004
20AF	NCBI ENTREZ ACCESSION NO. gi AB018273, Nagase, T. et al., June 16, 1999
20AG	NCBI ENTREZ ACCESSION NO. gi AB018306, Nagase, T. et al., January 10, 2004
20AH	NCBI ENTREZ ACCESSION NO. gi AB018324, Nagase, T. et al., May 10, 2002
20AI	NCBI ENTREZ ACCESSION NO. gi AB020661, Nagase, T. et al., January 10, 2004
20AJ	NCBI ENTREZ ACCESSION NO. gi AB023154, Nagase, T. et al., June 16, 1999
20AK	NCBI ENTREZ ACCESSION NO. gi AB023194, Nagase, T. et al., January 10, 2004
20AL	NCBI ENTREZ ACCESSION NO. gi AB026891, Sato, H. et al., February 10, 2001
20AM	NCBI ENTREZ ACCESSION NO. gi AB028957, Kikuno, R. et al., August 4, 1999
20AN	NCBI ENTREZ ACCESSION NO. gi AB029027, Kikuno, R. et al., January 10, 2004

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

21AA	NCBI ENTREZ ACCESSION NO. gi AC004472, Lamerdin, J.E. et al., June 15, 2001
21AB	NCBI ENTREZ ACCESSION NO. gi AC005329, Lamerdin, J.E. et al., July 28, 1998
21AC	NCBI ENTREZ ACCESSION NO. gi AF000560, Jansa, P. et al., May 31, 1997
21AD	NCBI ENTREZ ACCESSION NO. gi AF000561, Jansa, P. et al., May 31, 1997
21AE	NCBI ENTREZ ACCESSION NO. gi AF003837, Oda, T. et al., September 6, 1997
21AF	NCBI ENTREZ ACCESSION NO. gi AF007155, Andersson, B. et al., June 9, 1998
21AG	NCBI ENTREZ ACCESSION NO. gi AF007156, Andersson, B. et al., June 9, 1998
21AH	NCBI ENTREZ ACCESSION NO. gi AF009674, Vasicek, T.J. et al., July 15, 1997
21AI	NCBI ENTREZ ACCESSION NO. gi AF029670, Dosanjh, M.K. et al., February 24, 1998
21AJ	NCBI ENTREZ ACCESSION NO. gi AF030335, Communi, D. et al., July 16, 2002
21AK	NCBI ENTREZ ACCESSION NO. gi AF031824, Halfon, S. et al., June 24, 1998
21AL	NCBI ENTREZ ACCESSION NO. gi AF035299, Andersson, B. et al., July 7, 2000
21AM	NCBI ENTREZ ACCESSION NO. gi AF038172, Andersson, B. et al., January 22, 1998
21AN	NCBI ENTREZ ACCESSION NO. gi AF041259, Collins, C. et al., July 22, 1998

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

22AA	NCBI ENTREZ ACCESSION NO. gi AF045583, Nishina, P.M. et al., December 15, 1998
22AB	NCBI ENTREZ ACCESSION NO. gi AF055009, Andersson, B. et al., April 2, 1998
22AC	NCBI ENTREZ ACCESSION NO. gi AF061261, Du, G. et al., October 23, 1998
22AD	NCBI ENTREZ ACCESSION NO. gi AF068744, Ding, H. et al., September 13, 2001
22AE	NCBI ENTREZ ACCESSION NO. gi AF070530, Andersson, B. et al., August 5, 1998
22AF	NCBI ENTREZ ACCESSION NO. gi AF072247, Hendrich, B. et al., August 16, 1999
22AG	NCBI ENTREZ ACCESSION NO. gi AF093420, Raynes, D.A. et al., November 29, 1998
22AH	NCBI ENTREZ ACCESSION NO. gi AF102265, Matthijs, G. et al., November 10, 1998
22AI	NCBI ENTREZ ACCESSION NO. gi AF109134, Liu, J. et al., January 10, 1999
22AJ	NCBI ENTREZ ACCESSION NO. gi AF155654, Li, Y. et al., May 2, 2000
22AK	NCBI ENTREZ ACCESSION NO. gi AI038821, NCI-CGAP, June 30, 1998
22AL	NCBI ENTREZ ACCESSION NO. gi AI659108, NCI-CGAP, May 7, 1999
22AM	NCBI ENTREZ ACCESSION NO. gi AI761647, NCI-CGAP, June 24, 1999
22AN	NCBI ENTREZ ACCESSION NO. gi AI813532, NCI-CGAP, July 8, 1999

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

23AA	NCBI ENTREZ ACCESSION NO. gi AJ001685, Adamkiewicz, T.V. et al., September 4, 1998
23AB	NCBI ENTREZ ACCESSION NO. gi AJ011736, Kedra, D. et al., January 7, 1999
23AC	NCBI ENTREZ ACCESSION NO. gi AL031228, Tubby, B., September 26, 2001
23AD	NCBI ENTREZ ACCESSION NO. gi AL035307, Rhodes, S., January 28, 1999
23AE	NCBI ENTREZ ACCESSION NO. gi AL043470, Bloecker, H. et al., July 8, 1999
23AF	NCBI ENTREZ ACCESSION NO. gi AL049365, Wambutt, R. et al., August 3, 2004
23AG	NCBI ENTREZ ACCESSION NO. gi AL050025, Wambutt, R. et al., August 3, 2004
23AH	NCBI ENTREZ ACCESSION NO. gi AL050065, Koehrer, K. et al., February 18, 2000
23AI	NCBI ENTREZ ACCESSION NO. gi AL050290, Ansorge, W. et al., February 18, 2000
23AJ	NCBI ENTREZ ACCESSION NO. gi AL050345, Collins, J.E. et al., May 26, 1999
23AK	NCBI ENTREZ ACCESSION NO. gi D12763, Tominaga, S. et al., January 23, 2003
23AL	NCBI ENTREZ ACCESSION NO. gi D13413, Croyle, M.L. et al., February 14, 2003
23AM	NCBI ENTREZ ACCESSION NO. gi D16815, Kamizono, A. et al., February 4, 1999
23AN	NCBI ENTREZ ACCESSION NO. gi D26158, Sakai, K. et al., July 6, 1999

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

24AA	NCBI ENTREZ ACCESSION NO. gi D28118, Koyano-Nakagawa, N. et al., August 1, 2002
24AB	NCBI ENTREZ ACCESSION NO. gi D63390, Adachi, H. et al., February 13, 1999
24AC	NCBI ENTREZ ACCESSION NO. gi D67031, Katagiri, T. et al., December 10, 1997
24AD	NCBI ENTREZ ACCESSION NO. gi D83542, Shimoyama, Y. et al., October 30, 2000
24AE	NCBI ENTREZ ACCESSION NO. gi D85131, Tsutsui, H. et al., February 1, 2003
24AF	NCBI ENTREZ ACCESSION NO. gi D87119, Ohno, I. et al., March 11, 1998
24AG	NCBI ENTREZ ACCESSION NO. gi D89377, Iimura, T. et al., September 4, 1999
24AH	NCBI ENTREZ ACCESSION NO. gi J00277, Tabin, C.J. et al., February 13, 2004
24AI	NCBI ENTREZ ACCESSION NO. gi J04027, Verma, A.K. et al., August 19, 1995
24AJ	NCBI ENTREZ ACCESSION NO. gi J04599, Fisher, L.W. et al., June 11, 1993
24AK	NCBI ENTREZ ACCESSION NO. gi J05581, Gendler, S.J. et al., January 7, 1995
24AL	NCBI ENTREZ ACCESSION NO. gi K03498, Ono, M. et al., February 13, 1996
24AM	NCBI ENTREZ ACCESSION NO. gi L07261, Joshi, R. et al., May 6, 1993
24AN	NCBI ENTREZ ACCESSION NO. gi L07540, O'Donnell, M. et al., October 7, 1996

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

25AA	NCBI ENTREZ ACCESSION NO. gi L10678, Honore, B. et al., October 14, 1993
25AB	NCBI ENTREZ ACCESSION NO. gi L13463, Siderovski, D.P. et al., March 5, 1996
25AC	NCBI ENTREZ ACCESSION NO. gi L13972, Chang, M.L. et al., July 12, 1995
25AD	NCBI ENTREZ ACCESSION NO. gi L25665, Vernet, C. et al., May 16, 1995
25AE	NCBI ENTREZ ACCESSION NO. gi L32976, Ing, Y.L. et al., January 7, 1995
25AF	NCBI ENTREZ ACCESSION NO. gi L34059, Suzuki, S. et al., June 29, 1994
25AG	NCBI ENTREZ ACCESSION NO. gi L37033, Lam, E. et al., May 16, 1996
25AH	NCBI ENTREZ ACCESSION NO. gi L40802, Labrie, Y. et al., October 13, 1995
25AI	NCBI ENTREZ ACCESSION NO. gi L43821, Law, S.F. et al., May 1, 1996
25AJ	NCBI ENTREZ ACCESSION NO. gi M11717, Hunt, C. et al., November 8, 1994
25AK	NCBI ENTREZ ACCESSION NO. gi M14333, Semba, K. et al., March 27, 1998
25AL	NCBI ENTREZ ACCESSION NO. gi M22489, Wozney, J.M. et al., October 31, 1994
25AM	NCBI ENTREZ ACCESSION NO. gi M23115, Lytton, J. et al., November 15, 1994
25AN	NCBI ENTREZ ACCESSION NO. gi M28668, Riordan, J.R. et al., April 27, 1993

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

26AA	NCBI ENTREZ ACCESSION NO. gi M29893, Polakis, P.G. et al., April 27, 1993
26AB	NCBI ENTREZ ACCESSION NO. gi M31682, Feng, Z.M. et al., January 6, 1995
26AC	NCBI ENTREZ ACCESSION NO. gi M34064, Walsh, F.S. et al., November 17, 1993
26AD	NCBI ENTREZ ACCESSION NO. gi M34182, Beebe, S.J. et al., March 11, 1994
26AE	NCBI ENTREZ ACCESSION NO. gi M36089, Thompson, L.H. et al., March 7, 1995
26AF	NCBI ENTREZ ACCESSION NO. gi M57730, Holzman, L.B. et al., December 31, 1994
26AG	NCBI ENTREZ ACCESSION NO. gi M58603, Meyer, R. et al., April 27, 1993
26AH	NCBI ENTREZ ACCESSION NO. gi M60299, Ryan, M.C. et al., July 31, 1995
26AI	NCBI ENTREZ ACCESSION NO. gi M64174, Wilks, A.F. et al., April 27, 1993
26AJ	NCBI ENTREZ ACCESSION NO. gi M64571, West, R.R. et al., January 7, 1995
26AK	NCBI ENTREZ ACCESSION NO. gi M64788, Rubinfeld, B. et al., January 8, 1995
26AL	NCBI ENTREZ ACCESSION NO. gi M65066, Solberg, R. et al., November 10, 1994
26AM	NCBI ENTREZ ACCESSION NO. gi M69023, Wu, Y.J. et al., December 22, 1999
26AN	NCBI ENTREZ ACCESSION NO. gi M73077, LeClerc, S. et al., December 31, 1994

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

27AA	NCBI ENTREZ ACCESSION NO. gi M80482, Kiefer, M.C. et al., January 7, 1995
27AB	NCBI ENTREZ ACCESSION NO. gi M87339, Chen, M. et al., October 7, 1996
27AC	NCBI ENTREZ ACCESSION NO. gi M88458, Hsu, V.W. et al., April 27, 1993
27AD	NCBI ENTREZ ACCESSION NO. gi M96684, Bergemann, A.D. et al., January 8, 1995
27AE	NCBI ENTREZ ACCESSION NO. gi NM_004713, Carbonnelle, D. et al., August 23, 2004
27AF	NCBI ENTREZ ACCESSION NO. gi NM_006979, Taylor, K.M. et al., August 20, 2004
27AG	NCBI ENTREZ ACCESSION NO. gi NM_017432, Mittler, G. et al., August 21, 2004
27AH	NCBI ENTREZ ACCESSION NO. gi S37730, Binkert, C. et al., May 8, 1993
27AI	NCBI ENTREZ ACCESSION NO. gi S67070, Elisei, R. et al., February 5, 1994
27AJ	NCBI ENTREZ ACCESSION NO. gi S70154, Song, X.Q. et al., September 23, 1994
27AK	NCBI ENTREZ ACCESSION NO. gi U03688, Sutter, T.R. et al., July 6, 1994
27AL	NCBI ENTREZ ACCESSION NO. gi U09578, Sithanandam, G. et al., January 25, 1999
27AM	NCBI ENTREZ ACCESSION NO. gi U14971, Frigerio, J.M. et al., January 26, 1996
27AN	NCBI ENTREZ ACCESSION NO. gi U15655, Mavrothalassitis, G.J., February 3, 1996

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

28AA	NCBI ENTREZ ACCESSION NO. gi U19718, Faraco, J. et al., October 26, 1995
28AB	NCBI ENTREZ ACCESSION NO. gi U19775, Zervos, A.S. et al., December 29, 1995
28AC	NCBI ENTREZ ACCESSION NO. gi U21551, Schuldiner, O. et al., September 20, 1996
28AD	NCBI ENTREZ ACCESSION NO. gi U25138, Meera, P. et al., June 14, 1996
28AE	NCBI ENTREZ ACCESSION NO. gi U34994, Hartley, K.O. et al., April 12, 2001
28AF	NCBI ENTREZ ACCESSION NO. gi U37518, Wiley, S.R. et al., January 6, 1996
28AG	NCBI ENTREZ ACCESSION NO. gi U41344, Grover, J. et al., June 3, 1998
28AH	NCBI ENTREZ ACCESSION NO. gi U43368, Grimmond, S. et al., March 7, 1996
28AI	NCBI ENTREZ ACCESSION NO. gi U47025, Gelinas, R.P. et al., January 31, 1996
28AJ	NCBI ENTREZ ACCESSION NO. gi U51166, Neddermann, P. et al., June 18, 1996
28AK	NCBI ENTREZ ACCESSION NO. gi U51903, Brill, S. et al., December 5, 1996
28AL	NCBI ENTREZ ACCESSION NO. gi U52840, Simmons, A.D. et al., April 2, 1998
28AM	NCBI ENTREZ ACCESSION NO. gi U57057, Zaphiropoulos, P.G. et al., February 21, 1997
28AN	NCBI ENTREZ ACCESSION NO. gi U57352, Garcia-Anoveros, J. et al., March 11, 1997

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

29AA	NCBI ENTREZ ACCESSION NO. gi U65676, Oh, J. et al., February 11, 2002
29AB	NCBI ENTREZ ACCESSION NO. gi U67733, Rosman, G.J. et al., May 21, 1997
29AC	NCBI ENTREZ ACCESSION NO. gi U68111, Helps, N.R. et al., April 11, 1997
29AD	NCBI ENTREZ ACCESSION NO. gi U71364, Sun, J. et al., November 1, 1996
29AE	NCBI ENTREZ ACCESSION NO. gi U72649, Rouault, J.P. et al., December 4, 1996
29AF	NCBI ENTREZ ACCESSION NO. gi U79287, Andersson, B. et al., November 28, 2000
29AG	NCBI ENTREZ ACCESSION NO. gi U80040, Juang, H.H. et al., December 11, 1996
29AH	NCBI ENTREZ ACCESSION NO. gi U81561, Jiang, S. et al., September 3, 1997
29AI	NCBI ENTREZ ACCESSION NO. gi U84570, Pruijn, G.J.M. et al., February 10, 1997
29AJ	NCBI ENTREZ ACCESSION NO. gi U90902, Andersson, B. et al., March 29, 1997
29AK	NCBI ENTREZ ACCESSION NO. gi U93305, Fisher, S.E. et al., December 21, 1997
29AL	NCBI ENTREZ ACCESSION NO. gi U97067, Janssens, B. et al., November 10, 1999
29AM	NCBI ENTREZ ACCESSION NO. gi U97188, Mueller-Pillasch, F. et al., September 11, 1998
29AN	NCBI ENTREZ ACCESSION NO. gi W29065, Macke, J. et al., May 8, 1996

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

30AA	NCBI ENTREZ ACCESSION NO. gi W26652, Macke, J. et al., May 8, 1996
30AB	NCBI ENTREZ ACCESSION NO. gi W72186, Hillier, L. et al., June 19, 1996
30AC	NCBI ENTREZ ACCESSION NO. gi X06272, Hortsch, M. et al., September 12, 1993
30AD	NCBI ENTREZ ACCESSION NO. gi X06745, Wong, S.W. et al., July 26, 1995
30AE	NCBI ENTREZ ACCESSION NO. gi X12534, Pizon, V. et al., September 12, 1993
30AF	NCBI ENTREZ ACCESSION NO. gi X12794, Miyajima, N. et al., June 25, 1997
30AG	NCBI ENTREZ ACCESSION NO. gi X13293, Nomura, N. et al., September 12, 1993
30AH	NCBI ENTREZ ACCESSION NO. gi X13916, Herz, J. et al., April 18, 1996
30AI	NCBI ENTREZ ACCESSION NO. gi X60708, Misumi, Y. et al., November 16, 1993
30AJ	NCBI ENTREZ ACCESSION NO. gi X63629, Shimoyama, Y. et al., February 6, 1992
30AK	NCBI ENTREZ ACCESSION NO. gi X66435, Russ, A.P. et al., September 12, 1993
30AL	NCBI ENTREZ ACCESSION NO. gi X67325, Rasmussen, U.B. et al., December 3, 2000
30AM	NCBI ENTREZ ACCESSION NO. gi X70040, Ronsin, C. et al., May 26, 1993
30AN	NCBI ENTREZ ACCESSION NO. gi X70340, Qian, J.F. et al., December 7, 1993

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

31AA	NCBI ENTREZ ACCESSION NO. gi X74331, Stadlbauer, F. et al., September 9, 2004
31AB	NCBI ENTREZ ACCESSION NO. gi X74837, Bause, E. et al., November 15, 1993
31AC	NCBI ENTREZ ACCESSION NO. gi X76029, Austin, C. et al., October 5, 1995
31AD	NCBI ENTREZ ACCESSION NO. gi X76104, Deiss, L.P. et al., April 20, 1997
31AE	NCBI ENTREZ ACCESSION NO. gi X77909, Albertella, M.R. et al., May 31, 1994
31AF	NCBI ENTREZ ACCESSION NO. gi X78817, Tribioli, C. et al., May 7, 1996
31AG	NCBI ENTREZ ACCESSION NO. gi X78992, Nie, X.F. et al., May 3, 1995
31AH	NCBI ENTREZ ACCESSION NO. gi X79067, Barnard, R.C. et al., September 9, 2004
31AI	NCBI ENTREZ ACCESSION NO. gi X80507, Sudol, M. et al., September 26, 1995
31AJ	NCBI ENTREZ ACCESSION NO. gi X82207, Adams, M.D. et al., November 26, 1997
31AK	NCBI ENTREZ ACCESSION NO. gi X84373, Cavailles, V. et al., August 9, 1995
31AL	NCBI ENTREZ ACCESSION NO. gi X84740, Wei, Y.F. et al., February 16, 1996
31AM	NCBI ENTREZ ACCESSION NO. gi X85545, Klink, A. et al., June 5, 1997
31AN	NCBI ENTREZ ACCESSION NO. gi X90392, Coy, J.F. et al., September 2, 1996

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

32AA	NCBI ENTREZ ACCESSION NO. gi X90976, Levanon, D. et al., November 25, 1998
32AB	NCBI ENTREZ ACCESSION NO. gi X93209, Hospital, V. et al., November 25, 1997
32AC	NCBI ENTREZ ACCESSION NO. gi XM_212189, International Human Genome Sequencing Consortium, January 3, 2003
32AD	NCBI ENTREZ ACCESSION NO. gi Y00971, Iizasa, T. et al., September 12, 1993
32AE	NCBI ENTREZ ACCESSION NO. gi Y09846, Harun, R.B. et al., June 25, 1997
32AF	NCBI ENTREZ ACCESSION NO. gi Y10032, Waldegger, S. et al., May 16, 1997
32AG	NCBI ENTREZ ACCESSION NO. gi Y10055, Vanhaesebroeck, B. et al., October 2, 2003
32AH	NCBI ENTREZ ACCESSION NO. gi Y11395, Mayer, H. et al., September 11, 2001
32AI	NCBI ENTREZ ACCESSION NO. gi Y12661, Canu, N. et al., July 3, 1997
32AJ	NCBI ENTREZ ACCESSION NO. gi Y12781, Bassi, M.T. et al., May 19, 1999
32AK	NCBI ENTREZ ACCESSION NO. gi Y15227, Liu, Y. et al., December 4, 1997
32AL	NCBI ENTREZ ACCESSION NO. gi Y15521, Ried, K. et al., January 20, 2003
32AM	NCBI ENTREZ ACCESSION NO. gi Y16241, Millevoi, S. et al., September 25, 1998
32AN	NCBI ENTREZ ACCESSION NO. gi Y17711, Natter, S. et al., July 7, 1998

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0185 US PCT
APPLICATION NO.
10/501,035
APPLICANT
HUANG ET AL.
FILING DATE
JULY 9, 2004

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

33AA	NCBI ENTREZ ACCESSION NO. gi Y18483, Borsani, G. et al., April 24, 1999
33AB	NCBI ENTREZ ACCESSION NO. gi Z74615, Bernard, M.P. et al., March 7, 1997
AC	
AD	
AE	
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.